Caribou Biosciences, Inc. (NasdaqGS: CRBU)
Health Care · Biotechnology · US
$1.66
+3.11% today · -10.3% 1Y
Caribou Biosciences, Inc. (NasdaqGS: CRBU) operates in the Biotechnology industry within the Health Care sector. The company is valued at $177.96M and employs 97 people.
Over the last twelve months the share price has lost 10.3%, trading between 1.38 and 3.54.
Tweenvest scores Caribou Biosciences, Inc. across four factors: quality 26/100, value 56/100, growth 66/100. Its strongest factor is growth.
CRBU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $177.96M
- Revenue (TTM)
- $10.04M
- P/E
- —
- EPS
- -1.08
- Dividend yield
- —
- Beta (5Y)
- 2.28
- 52-week high
- $3.54
- 52-week low
- $1.38
- Avg volume (3M)
- —
- Shares outstanding
- 107.21M
- Employees
- 97
- Next earnings
- —
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
- Founded
- 2011
- Listed since
- Jul 23, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.